JMP Securities Maintains Market Outperform on Terns Pharma, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
JMP Securities has maintained a Market Outperform rating on Terns Pharma and increased its price target from $15 to $20.
September 10, 2024 | 11:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has raised the price target for Terns Pharma from $15 to $20 while maintaining a Market Outperform rating, indicating positive expectations for the company's stock performance.
The increase in price target from $15 to $20 by JMP Securities suggests a positive outlook for Terns Pharma's stock. Maintaining a Market Outperform rating indicates that the analyst expects the stock to perform better than the market average, which could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100